{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:58:02Z","timestamp":1786985882223,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"am","delay-in-days":343,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-22-1-0729"],"award-info":[{"award-number":["W81XWH-22-1-0729"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.cct.2023.107106","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T14:20:07Z","timestamp":1675347607000},"page":"107106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Low-dose ketamine infusion for the treatment of multiple sclerosis fatigue (INKLING-MS): Study protocol for a randomized, double-blind, active placebo-controlled phase II trial"],"prefix":"10.1016","volume":"126","author":[{"given":"Mahsa","family":"Ghajarzadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Vega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bardia","family":"Nourbakhsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.cct.2023.107106_bb0005","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/S1474-4422(05)70166-6","article-title":"Quality of life and its assessment in multiple sclerosis: integrating physical and psychological components of wellbeing","volume":"4","author":"Mitchell","year":"2005","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.cct.2023.107106_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6963-14-286","article-title":"Updated cost-of-care estimates for commercially insured patients with multiple sclerosis: retrospective observational analysis of medical and pharmacy claims data","volume":"14","author":"Carroll","year":"2014","journal-title":"BMC Health Serv. Res."},{"issue":"3","key":"10.1016\/j.cct.2023.107106_bb0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S1474-4422(18)30443-5","article-title":"Global, regional, and national burden of multiple sclerosis 1990\u20132016: a systematic analysis for the global burden of disease study 2016","volume":"18","author":"Wallin","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cct.2023.107106_bb0020","series-title":"Fatigue is Intrinsic to Multiple Sclerosis (MS) and is the Most Commonly Reported Symptom of the Disease","first-page":"367","author":"Krupp","year":"2006"},{"issue":"12","key":"10.1016\/j.cct.2023.107106_bb0025","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1111\/j.1468-1331.2007.01974.x","article-title":"A prospective study of patterns of fatigue in multiple sclerosis","volume":"14","author":"Lerdal","year":"2007","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.cct.2023.107106_bb0030","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13760-013-0198-2","article-title":"Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex","volume":"113","author":"Ghajarzadeh","year":"2013","journal-title":"Acta Neurol. Belg."},{"key":"10.1016\/j.cct.2023.107106_bb0035","series-title":"Fatigue, Depression and Sleep Disturbances Iniranian Patients with Multiple Sclerosis","author":"Ghajarzadeh","year":"2012"},{"issue":"9413","key":"10.1016\/j.cct.2023.107106_bb0040","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(04)15794-2","article-title":"Fatigue in neurological disorders","volume":"363","author":"Chaudhuri","year":"2004","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cct.2023.107106_bb0045","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1212\/WNL.0b013e31827f07be","article-title":"Fatigue and fatigability in neurologic illnesses: proposal for a unified taxonomy","volume":"80","author":"Kluger","year":"2013","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.cct.2023.107106_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-020-61076-1","article-title":"Fatigue profiles in patients with multiple sclerosis are based on severity of fatigue and not on dimensions of fatigue","volume":"10","author":"Beckerman","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.cct.2023.107106_bb0055","article-title":"Exercise therapy for fatigue in multiple sclerosis","volume":"9","author":"Heine","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.cct.2023.107106_bb0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jocn.2018.03.024","article-title":"Cognitive behavioral therapies and multiple sclerosis fatigue: a review of literature","volume":"52","author":"Chalah","year":"2018","journal-title":"J. Clin. Neurosci."},{"issue":"1","key":"10.1016\/j.cct.2023.107106_bb0065","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/S1474-4422(20)30354-9","article-title":"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial","volume":"20","author":"Nourbakhsh","year":"2021","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.cct.2023.107106_bb0070","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.ajem.2018.11.026","article-title":"Intranasal ketamine reduces pain of digital nerve block; a double blind randomized clinical trial","volume":"37","author":"Nejati","year":"2019","journal-title":"Am. J. Emerg. Med."},{"issue":"5","key":"10.1016\/j.cct.2023.107106_bb0075","doi-asserted-by":"crossref","first-page":"444","DOI":"10.2174\/1570159X12666140619204251","article-title":"The role of ketamine in treatment-resistant depression: a systematic review","volume":"12","author":"Serafini","year":"2014","journal-title":"Curr. Neuropharmacol."},{"issue":"2","key":"10.1016\/j.cct.2023.107106_bb0080","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.genhosppsych.2015.01.003","article-title":"Ketamine as a novel treatment for major depressive disorder and bipolar depression: a systematic review and quantitative meta-analysis","volume":"37","author":"Lee","year":"2015","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"4","key":"10.1016\/j.cct.2023.107106_bb0085","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0006-3223(99)00230-9","article-title":"Antidepressant effects of ketamine in depressed patients","volume":"47","author":"Berman","year":"2000","journal-title":"Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.cct.2023.107106_bb0090","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/archpsyc.63.8.856","article-title":"A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression","volume":"63","author":"Zarate","year":"2006","journal-title":"Arch. Gen. Psychiatry"},{"issue":"10","key":"10.1016\/j.cct.2023.107106_bb0095","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1176\/appi.ajp.2013.13030392","article-title":"Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial","volume":"170","author":"Murrough","year":"2013","journal-title":"Am. J. Psychiatr."},{"key":"10.1016\/j.cct.2023.107106_bb0100","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jad.2016.01.009","article-title":"An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder","volume":"194","author":"Saligan","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.cct.2023.107106_bb0105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jad.2018.10.089","article-title":"Disentangling the association of depression on the anti-fatigue effects of ketamine","volume":"244","author":"Saligan","year":"2019","journal-title":"J. Affect. Disord."},{"issue":"6","key":"10.1016\/j.cct.2023.107106_bb0110","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1177\/1352458520936226","article-title":"Pilot randomized active-placebo-controlled trial of low-dose ketamine for the treatment of multiple sclerosis\u2013related fatigue","volume":"27","author":"Fitzgerald","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.cct.2023.107106_bb0115","article-title":"Tired of not knowing what that fatigue score means? Normative data of the modified fatigue impact scale (MFIS)","volume":"46","author":"Strober","year":"2020","journal-title":"Multiple Scler. Relat. Dis."},{"issue":"11","key":"10.1016\/j.cct.2023.107106_bb0120","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1177\/1352458521996002","article-title":"Which exercise and behavioural interventions show most promise for treating fatigue in multiple sclerosis? A network meta-analysis","volume":"27","author":"Harrison","year":"2021","journal-title":"Mult. Scler. J."},{"issue":"11","key":"10.1016\/j.cct.2023.107106_bb0125","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1001\/jamaneurol.2015.2332","article-title":"Association between glutamate blockade and fatigue in patients with multiple sclerosis","volume":"72","author":"Nourbakhsh","year":"2015","journal-title":"JAMA Neurol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714423000290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714423000290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T14:41:43Z","timestamp":1782484903000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714423000290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":25,"alternative-id":["S1551714423000290"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2023.107106","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Low-dose ketamine infusion for the treatment of multiple sclerosis fatigue (INKLING-MS): Study protocol for a randomized, double-blind, active placebo-controlled phase II trial","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2023.107106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107106"}}